Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Temozolomide in malignant gliomas.

W K Yung1

  • 1Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030-4009, USA.

Seminars in Oncology
|June 24, 2000
PubMed
Summary

Temozolomide (TMZ) is a promising oral chemotherapy for malignant gliomas. Clinical studies show it effectively delays disease progression and maintains quality of life in patients with these brain tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Success rate of induction of labour in twin pregnancies relative to singleton pregnancies in a predominantly Chinese population.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

A brief group intervention using a cognitive-behavioural approach to reduce postnatal depressive symptoms: a randomised controlled trial.

Hong Kong medical journal = Xianggang yi xue za zhi·2016
Same author

Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas.

Oncotarget·2016
Same author

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.

Journal of neuro-oncology·2015
Same author

Social obstetrics: non-local expectant mothers admitted through accident and emergency department in a public hospital in Hong Kong.

Hong Kong medical journal = Xianggang yi xue za zhi·2014
Same author

The somatic genomic landscape of glioblastoma.

Cell·2013

Area of Science:

  • Neuro-oncology
  • Medical oncology
  • Pharmacology

Background:

  • Glioblastoma multiforme and anaplastic astrocytoma are aggressive primary central nervous system malignancies.
  • Current treatments offer limited efficacy, leading to significant morbidity and mortality.

Purpose of the Study:

  • To evaluate the efficacy and safety of Temozolomide (TMZ) in patients with malignant glioma.
  • To assess TMZ's impact on disease progression and health-related quality of life.

Main Methods:

  • Three open-label, multi-institutional studies evaluated 525 patients with malignant gliomas.
  • Rigorous controls included prospectively defined response criteria, central histology review, and validated quality-of-life assessments.

Main Results:

  • Temozolomide (TMZ) demonstrated antitumor activity in malignant gliomas.
  • TMZ was effective in delaying disease progression.
  • TMZ helped maintain health-related quality of life in patients.

Conclusions:

  • Temozolomide (TMZ) shows meaningful efficacy and an acceptable safety profile for malignant glioma treatment.
  • TMZ represents a promising new therapeutic option for patients with brain tumors.
  • TMZ's favorable pharmacokinetic profile (rapid CSF penetration, 100% oral bioavailability) supports its clinical utility.

Related Experiment Videos